# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Josh Schimmer reiterates Krystal Biotech (NASDAQ:KRYS) with a Overweight.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $221 pric...
HC Wainwright & Co. analyst Joseph Pantginis maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price tar...
Evercore ISI Group analyst Gavin Clark-Gartner maintains Krystal Biotech (NASDAQ:KRYS) with a Outperform and raises the pric...
Citigroup analyst Yigal Nochomovitz downgrades Krystal Biotech (NASDAQ:KRYS) from Buy to Neutral and raises the price target...
Chardan Capital analyst Geulah Livshits maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from ...